Arcus deprioritizes Gilead-partnered drug in prostate cancer, the latest hiccup in $1.6B collaboration

Ar­cus Bio­sciences is re­duc­ing fur­ther in­vest­ment on its adeno­sine re­cep­tor an­tag­o­nist in prostate can­cer af­ter re­view­ing in­ter­im da­ta, ac­cord­ing to its sec­ond quar­ter re­port.

In a press re­lease Mon­day morn­ing, Ar­cus and its part­ner Gilead said they re­viewed pro­gres­sion-free sur­vival da­ta from a Phase Ib/II study, dubbed ARC-6, and de­cid­ed to de­pri­or­i­tize fur­ther de­vel­op­ment of etru­madenant, an an­tag­o­nist of two adeno­sine re­cep­tors (A2a and A2b). The study was test­ing etru­madenant and zim­bere­limab, Ar­cus’ ex­per­i­men­tal an­ti-PD-1 drug, on top of do­c­etax­el ver­sus do­c­etax­el alone in 70 pa­tients with metasta­t­ic cas­trate-re­sis­tant prostate can­cer (mCR­PC).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.